Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17085580
Xie M, et al. (2006) A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A 103, 17378-83 17085580
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S79-p - ACC1 (mouse)
Modsite: FHMRSsMsGLHLVKQ SwissProt Entrez-Gene
Orthologous residues
ACC1 (human): S80‑p, ACC1 iso2 (human): S22‑p, ACC1 iso4 (human): S117‑p, ACC1 (mouse): S79‑p, ACC1 iso2 (mouse): S117‑p, ACC1 (rat): S79‑p, ACC1 iso2 (rat): S79‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) decrease dominant negative
oligomycin increase
oligomycin TAK1 (mouse) inhibit treatment-induced increase dominant negative
metformin increase
metformin TAK1 (mouse) inhibit treatment-induced increase dominant negative
HGK (mouse) increase
TAK1 (mouse) HGK (mouse) inhibit treatment-induced increase dominant negative
TAK1 (mouse) decrease homozygous null

T183-p - AMPKA1 (mouse)
Modsite: sDGEFLRtsCGsPNY SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) decrease dominant negative
oligomycin increase
oligomycin TAK1 (mouse) inhibit treatment-induced increase dominant negative
metformin increase
metformin TAK1 (mouse) inhibit treatment-induced increase dominant negative
HGK (mouse) increase
TAK1 (mouse) HGK (mouse) inhibit treatment-induced increase dominant negative
acadesine increase
ischemia increase
TAK1 (mouse) decrease homozygous null

T172-p - AMPKA2 (mouse)
Modsite: sDGEFLRtsCGsPNY SwissProt Entrez-Gene
Orthologous residues
AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) decrease dominant negative
oligomycin increase
oligomycin TAK1 (mouse) inhibit treatment-induced increase dominant negative
metformin increase
metformin TAK1 (mouse) inhibit treatment-induced increase dominant negative
HGK (mouse) increase
TAK1 (mouse) HGK (mouse) inhibit treatment-induced increase dominant negative
acadesine increase
ischemia increase
TAK1 (mouse) decrease homozygous null

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) no change compared to control dominant negative

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) no change compared to control dominant negative

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) no change compared to control dominant negative

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) no change compared to control dominant negative

T183-p - JNK1 (mouse)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) decrease dominant negative
HGK (mouse) increase
TAK1 (mouse) HGK (mouse) inhibit treatment-induced increase dominant negative

Y185-p - JNK1 (mouse)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) decrease dominant negative
HGK (mouse) increase
TAK1 (mouse) HGK (mouse) inhibit treatment-induced increase dominant negative

T180-p - P38A (mouse)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) decrease dominant negative

Y182-p - P38A (mouse)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  heart, MEF (fibroblast), myocyte-heart
Cellular systems studied:  primary cells, primary cultured cells, tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (mouse) decrease dominant negative